ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 9.31
-0.31 (-3.22%)
Jun 11, 2026, 3:04 PM CST
SHE:300254 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 17.8 | 24.85 | 42.19 | 25.2 | -118.52 | -91.44 |
Depreciation & Amortization | 58.41 | 58.41 | 58.25 | 58.53 | 64.79 | 66.93 |
Other Amortization | 2.95 | 2.95 | 1.02 | 0.85 | 0.75 | 0.74 |
Loss (Gain) From Sale of Assets | -8.94 | -8.94 | -7.51 | -18.8 | -0.69 | 0.37 |
Asset Writedown & Restructuring Costs | 0.43 | 0.43 | 5.67 | 5.51 | 48.4 | 31.68 |
Loss (Gain) From Sale of Investments | -3.97 | -3.97 | -4.54 | -20.88 | 3.43 | -13.64 |
Provision & Write-off of Bad Debts | 5.08 | 5.08 | 5.78 | -0.43 | 0.71 | -5.32 |
Other Operating Activities | 99.55 | 76.56 | 52.64 | 56.12 | 68.93 | 73.92 |
Change in Accounts Receivable | -40.67 | -40.67 | -71.14 | -5.35 | -120.83 | 119.48 |
Change in Inventory | -2.3 | -2.3 | -28.39 | -20.61 | 3.81 | 6.31 |
Change in Accounts Payable | -36.67 | -36.67 | 13.4 | -40.02 | 123.41 | -91.56 |
Change in Other Net Operating Assets | 24.17 | 24.17 | 13.48 | - | - | - |
Operating Cash Flow | 112.71 | 96.77 | 70.94 | 37.81 | 74.88 | 96.92 |
Operating Cash Flow Growth | 177.53% | 36.41% | 87.60% | -49.50% | -22.75% | - |
Capital Expenditures | -33.08 | -34.32 | -51.5 | -33.92 | -26.78 | -36.93 |
Sale of Property, Plant & Equipment | 0.93 | 0.35 | 0.21 | 100.83 | 2.12 | 6.42 |
Divestitures | - | - | 1.63 | - | - | -0.27 |
Investment in Securities | -147.41 | -60.29 | -202.84 | 5.19 | 1.47 | 5.57 |
Other Investing Activities | 3.6 | 2.36 | 4.23 | - | - | - |
Investing Cash Flow | -175.97 | -91.89 | -248.27 | 72.1 | -23.2 | -25.21 |
Short-Term Debt Issued | - | - | 1.8 | - | - | - |
Long-Term Debt Issued | - | 286.3 | 321.62 | 115.75 | 271.6 | 100.9 |
Total Debt Issued | 315.8 | 286.3 | 323.42 | 115.75 | 271.6 | 100.9 |
Short-Term Debt Repaid | - | - | -1.8 | - | - | - |
Long-Term Debt Repaid | - | -305.08 | -144.7 | -138.74 | -223.42 | -218.32 |
Total Debt Repaid | -288.09 | -305.08 | -146.5 | -138.74 | -223.42 | -218.32 |
Net Debt Issued (Repaid) | 27.71 | -18.78 | 176.93 | -22.99 | 48.18 | -117.42 |
Issuance of Common Stock | 43.96 | 43.96 | 33.35 | - | 105.25 | - |
Repurchase of Common Stock | -0.29 | -0.29 | -1.66 | -203.24 | - | - |
Common Dividends Paid | -18.09 | -18.97 | -12.32 | -13.31 | -11.9 | -14.67 |
Other Financing Activities | 60.55 | 1 | -1.45 | -2.23 | -28.96 | -20.21 |
Financing Cash Flow | 113.85 | 6.93 | 194.84 | -241.77 | 112.56 | -152.3 |
Net Cash Flow | 50.59 | 11.8 | 17.51 | -131.85 | 164.24 | -80.58 |
Free Cash Flow | 79.63 | 62.45 | 19.44 | 3.9 | 48.09 | 59.99 |
Free Cash Flow Growth | 200.81% | 221.25% | 398.72% | -91.90% | -19.84% | - |
Free Cash Flow Margin | 9.23% | 7.17% | 2.30% | 0.49% | 5.80% | 6.45% |
Free Cash Flow Per Share | 0.32 | 0.26 | 0.08 | 0.02 | 0.20 | 0.26 |
Cash Income Tax Paid | 128.73 | 125.29 | 96.53 | 116.45 | 89.17 | 89.28 |
Levered Free Cash Flow | 116.85 | 170.49 | -82.9 | -157.05 | 316.58 | 23.16 |
Unlevered Free Cash Flow | 129.99 | 184.01 | -72.29 | -136.33 | 345.37 | 53.89 |
Change in Working Capital | -58.59 | -58.59 | -82.56 | -68.28 | 7.07 | 33.67 |